Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)
Launched by PETER ONG, MD · Jun 12, 2009
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the causes of chest pain and shortness of breath in patients who are suspected of having coronary artery disease (CAD) but have normal coronary arteries. Researchers are using a special test called the acetylcholine test to see if the blood vessels are reacting abnormally, which could lead to coronary spasms—this is when the arteries temporarily tighten and can cause symptoms. By finding out if there’s a spasm, doctors can better treat patients with the right medications and possibly help avoid more invasive tests in the future.
To participate in this study, you should be an adult between 35 and 95 years old, experiencing chest pain or breathing difficulties related to heart issues, and have already undergone tests suggesting a heart problem. You should also have normal kidney function and a good heart pumping ability. If you join the study, you can expect to undergo the acetylcholine test and provide blood samples so researchers can look for other factors related to coronary spasms. Your involvement could help improve understanding and treatment of these heart-related symptoms for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults between 35 and 95 years old with angina pectoris and/or dyspnea suggestive of coronary artery disease with non-invasive proof of coronary ischemia or high pre-test probability for CAD who will be referred for coronary angiography
- • Serum creatinine \< 1,4 md/dl
- • Left ventricular ejection fraction \> 50%
- Exclusion Criteria:
- • Patients under 35 years and above 95 years of age
- • Severe chronic obstructive pulmonary disease (contraindication for acetylcholine-testing)
About Peter Ong, Md
Dr. Peter Ong, MD, is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical oncology and a robust background in trial design and implementation, Dr. Ong leads innovative studies that explore cutting-edge therapies and treatment modalities. His dedication to ethical research practices and patient safety ensures that his trials not only adhere to regulatory standards but also prioritize participant welfare. Dr. Ong's collaborative approach fosters partnerships with leading research institutions, making significant contributions to the field and enhancing the development of new therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stuttgart, , Germany
Patients applied
Trial Officials
Peter Ong, MD
Principal Investigator
Robert Bosch Medical Center
Andreas Seitz, MD
Study Chair
Robert Bosch Medical Center
Udo Sechtem, MD
Study Director
Robert Bosch Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials